Research Article

Comparison between Clinical Utility of CXCL-8 and Clinical Practice Tumor Markers for Colorectal Cancer Diagnosis

Table 5

Spearman’s rank correlations between the serum concentrations of CXCL-8, CEA, and CA19-9 and the clinicopathological characteristics among patients with colorectal cancer.

TNM stageT stageN stageM stageTumor sizeHistological gradeVascular invasionNerve invasionCEACA19-9CXCL-8

TNM stage1.0000.6780.8750.4560.0850.146-0.151-0.2740.2650.1360.075
<0.001<0.001<0.0010.1020.0140.012<0.001<0.0010.0210.131

T stage0.6781.0000.4460.3240.1580.207-0.114-0.3190.2440.1390.048
<0.001<0.001<0.0010.0090.0010.044<0.001<0.0010.0180.237

N stage0.8750.4461.0000.400-0.0440.143-0.128-0.1790.1860.1040.037
<0.001<0.001<0.0010.2570.0160.0270.0030.0020.0600.290

M stage0.4560.3240.4001.0000.0290.109-0.084-0.0970.2770.1810.117
<0.001<0.001<0.0010.3340.0500.1030.072<0.0010.0030.039

Tumor size0.0850.158-0.0440.0291.0000.093-0.012-0.1880.1730.0700.122
0.1020.0090.2570.3340.0800.4310.0020.0050.1480.034

Histological
Grade
0.1460.2070.1430.1090.0931.0000.099-0.0550.0640.1250.001
0.0140.0010.0160.0500.0800.0690.2040.1680.0300.493

Vascular invasion-0.151-0.114-0.128-0.084-0.0120.0991.0000.231-0.046-0.0550.028
0.0120.0440.0270.1030.4310.069<0.0010.2470.2030.335

Nerve invasion-0.274-0.319-0.179-0.097-0.188-0.0550.2311.000-0.202-0.118-0.067
<0.001<0.0010.0030.0720.0020.204<0.0010.0010.0390.159

CEA0.2650.2440.1860.2770.1730.064-0.046-0.2021.0000.4230.015
<0.001<0.0010.002<0.0010.0050.1680.2470.001<0.0010.409

CA19-90.1360.1390.1040.1810.0700.125-0.055-0.1180.4231.000-0.001
0.0210.0180.0600.0030.1480.0300.2030.039<0.0010.491

CXCL-80.0750.0480.0370.1170.1220.0010.028-0.0670.015-0.0011.000
0.1310.2370.2900.0390.0340.4930.3350.1590.4090.491

, (bold).